Market closed

Perspective Therapeutics/$CATX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Perspective Therapeutics

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Ticker

$CATX

Trading on

AMEX

Industry

Biotechnology

Employees

139

CATX Metrics

BasicAdvanced
$133M
-
-$1.23
1.26
-
$133M
1.26
$19.05
$1.62
701K
12.68
12.529
1.05
1.397
-1,391.60%
-19.02%
-42.82%
79.759
0.44
0.53
-1.595
1.39%
-29.18%

What the Analysts think about CATX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Perspective Therapeutics stock.
0.00%20.00%40.00%60.00%80.00%100.00%JulAugSeptOctNovDecJanFebMarAprMayJun

CATX Financial Performance

$0$10B$20B$30B$40B$50B$60BQ4 23Q1 24Q2 24Q3 24

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CATX Earnings Performance

$0.00$1.00$2.00$3.00Q4 23BeatQ1 24BeatQ2 24BeatQ3 24BeatQ4 24-

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CATX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

FAQs

What’s the current market cap for Perspective Therapeutics stock?

Perspective Therapeutics (CATX) has a market cap of $133M as of April 08, 2025.

What is the P/E ratio for Perspective Therapeutics stock?

The price to earnings (P/E) ratio for Perspective Therapeutics (CATX) stock is 0 as of April 08, 2025.

Does Perspective Therapeutics stock pay dividends?

No, Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders as of April 08, 2025.

When is the next Perspective Therapeutics dividend payment date?

Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders.

What is the beta indicator for Perspective Therapeutics?

Perspective Therapeutics (CATX) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Can we use optional cookies? View our Cookie Policy for details.

pixel